116 related articles for article (PubMed ID: 12778354)
1. [18-FDG-PET-findings in children and adolescents with Hodgkin's disease: retrospective evaluation of the correlation to other imaging procedures in initial staging and to the predictive value of follow up examinations].
Wickmann L; Lüders H; Dörffel W
Klin Padiatr; 2003; 215(3):146-50. PubMed ID: 12778354
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.
Lang O; Bihl H; Hültenschmidt B; Sautter-Bihl ML
Strahlenther Onkol; 2001 Mar; 177(3):138-44. PubMed ID: 11285771
[TBL] [Abstract][Full Text] [Related]
4. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Belhocine T; Hustinx R; Rigo P; Fillet G
Ann Oncol; 2003 Jan; 14(1):123-30. PubMed ID: 12488304
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease.
Kabickova E; Sumerauer D; Cumlivska E; Drahokoupilova E; Nekolna M; Chanova M; Hladikova M; Kodet R; Belohlavek O
Eur J Nucl Med Mol Imaging; 2006 Sep; 33(9):1025-31. PubMed ID: 16565847
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma.
Dittmann H; Sokler M; Kollmannsberger C; Dohmen BM; Baumann C; Kopp A; Bares R; Claussen CD; Kanz L; Bokemeyer C
Oncol Rep; 2001; 8(6):1393-9. PubMed ID: 11605073
[TBL] [Abstract][Full Text] [Related]
7. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol.
Körholz D; Kluge R; Wickmann L; Hirsch W; Lüders H; Lotz I; Dannenberg C; Hasenclever D; Dörffel W; Sabri O
Onkologie; 2003 Oct; 26(5):489-93. PubMed ID: 14605468
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.
Wiedmann E; Baican B; Hertel A; Baum RP; Chow KU; Knupp B; Adams S; Hör G; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Aug; 34(5-6):545-51. PubMed ID: 10492078
[TBL] [Abstract][Full Text] [Related]
9. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
10. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
[TBL] [Abstract][Full Text] [Related]
11. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
[TBL] [Abstract][Full Text] [Related]
12. PET imaging in pediatric Hodgkin's lymphoma.
Hudson MM; Krasin MJ; Kaste SC
Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
[TBL] [Abstract][Full Text] [Related]
13. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
[TBL] [Abstract][Full Text] [Related]
14. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.
Körholz D; Claviez A; Hasenclever D; Kluge R; Hirsch W; Kamprad F; Dörffel W; Wickmann L; Papsdorf K; Dieckmann K; Kahn T; Mauz-Körholz C; Dannenberg C; Pötter R; Brosteanu O; Schellong G; Sabri O
Klin Padiatr; 2004; 216(3):150-6. PubMed ID: 15175959
[TBL] [Abstract][Full Text] [Related]
15. [Clinical value of FDG PET using coincident gamma cameras in staging and restaging of malignant lymphoma--compared with convenitonal diagnostic methods].
Pichler R; Maschek W; Hatzl-Griesenhofer M; Huber H; Wimmer G; Wahl G; Fridrik M
Nuklearmedizin; 2000 Sep; 39(6):166-73. PubMed ID: 11057408
[TBL] [Abstract][Full Text] [Related]
16. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
17. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
18. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
[TBL] [Abstract][Full Text] [Related]
19. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
